Is darbepoetin alfa approved?

Yes. It is FDA- and EMA-approved (as Aranesp) for anaemia of chronic kidney disease and chemotherapy-induced anaemia in non-myeloid cancer.

What did the TREAT trial show?

In type 2 diabetes and CKD, darbepoetin did not reduce death or cardiovascular/renal events and about doubled the risk of stroke, reinforcing the ESA boxed warning.

Does darbepoetin carry the same warnings as other ESAs?

Yes. It shares the ESA boxed warning for death, cardiovascular events, thromboembolism and, in some cancers, shortened survival or tumour progression.

Is darbepoetin banned in sport?

Yes. It is on the WADA Prohibited List as a blood-doping agent.

EMA-approvedaka Aranesp

Darbepoetin alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Darbepoetin alfa (also known as Aranesp) is a peptide catalogued under Immune (Hyperglycosylated EPO). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Darbepoetin alfa?

Darbepoetin alfa (Aranesp) is a hyperglycosylated, long-acting analogue of erythropoietin: two extra N-linked carbohydrate chains slow its clearance, giving roughly a threefold longer terminal half-life than epoetin alfa and allowing less frequent dosing. It is FDA- and EMA-approved.

It is approved for anaemia of chronic kidney disease and for chemotherapy-induced anaemia in patients with non-myeloid malignancies. As an erythropoiesis-stimulating agent it shares the ESA class boxed warning.

Like erythropoietin, darbepoetin alfa is prohibited by WADA as a blood-doping agent.

How does Darbepoetin alfa work?

Darbepoetin alfa binds and activates the same erythropoietin receptor on marrow erythroid progenitors, stimulating red-cell production; its added sialic-acid-rich glycosylation extends its half-life rather than changing the underlying mechanism.

As with epoetin, the erythropoietic response is iron-dependent and develops over weeks.

What does the research say about Darbepoetin alfa?

Darbepoetin alfa has an approximately threefold longer terminal half-life than epoetin alfa in dialysis patients, enabling less frequent dosing. ^[1]
In a phase III trial in lung-cancer patients receiving chemotherapy, darbepoetin alfa reduced the need for red-cell transfusion versus placebo. ^[3]
In previously untreated extensive-stage small-cell lung cancer treated with platinum and etoposide, darbepoetin alfa reduced transfusion requirements without a demonstrable adverse effect on survival in that specific trial. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients — Macdougall IC et al., Journal of the American Society of Nephrology 1999. (Human pharmacokinetic study)
[2] A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease — Pfeffer MA et al., The New England Journal of Medicine 2009. (Randomized controlled trial (TREAT))
[3] Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy — Vansteenkiste J et al., Journal of the National Cancer Institute 2002. (Randomized controlled trial)
[4] Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide — Pirker R et al., Journal of Clinical Oncology 2008. (Randomized controlled trial)
[5] Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia — Bennett CL et al., JAMA 2008. (Meta-analysis)
[6] Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials — Bohlius J et al., Lancet 2009. (Meta-analysis of randomized trials)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In approved use, prescribers give the lowest darbepoetin dose that avoids transfusion and cap the haemoglobin target, because TREAT and the CKD ESA trials showed higher targets add stroke and cardiovascular risk without benefit.

This is context only, not medical advice; dosing and target haemoglobin are individualized and monitored by a clinician.

Side effects & safety profile

Darbepoetin alfa carries the same ESA FDA boxed warning as epoetin: increased death, myocardial infarction, stroke, venous thromboembolism and vascular-access thrombosis, and shortened survival or tumour progression in some cancers. In the large TREAT trial in type 2 diabetes and CKD, darbepoetin did not reduce death or cardiovascular/renal events and roughly doubled the risk of fatal or non-fatal stroke.

Class analyses in oncology (Bohlius meta-analysis; Bennett JAMA analysis) link ESAs, including darbepoetin, to excess venous thromboembolism and mortality, so it should be reserved for chemotherapy-induced anaemia and stopped after the chemotherapy course, avoiding haemoglobin above about 11 g/dL.

Darbepoetin alfa is WADA-prohibited; non-therapeutic use to raise haematocrit is doping and carries thrombotic risk.

Stacking & combinations

As with erythropoietin, darbepoetin is combined with iron repletion rather than other peptides, because iron availability limits the erythropoietic response.

Finding Darbepoetin alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a hyperglycosylated analogue with two extra carbohydrate chains, giving roughly a threefold longer half-life and allowing less frequent dosing, but it acts on the same erythropoietin receptor.

References

[1] Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients — Macdougall IC et al., Journal of the American Society of Nephrology 1999. PMID: 10541299. View sourceStudy: Human pharmacokinetic studyDarbepoetin alfa (NESP) had an approximately threefold longer terminal half-life than epoetin alfa, supporting less frequent dosing.
[2] A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease — Pfeffer MA et al., The New England Journal of Medicine 2009. PMID: 19880844. View sourceStudy: Randomized controlled trial (TREAT)Darbepoetin did not reduce death or cardiovascular/renal events and roughly doubled the risk of stroke.
[3] Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy — Vansteenkiste J et al., Journal of the National Cancer Institute 2002. PMID: 12189224. View sourceStudy: Randomized controlled trialDarbepoetin alfa reduced red-cell transfusion requirements versus placebo in chemotherapy-associated anaemia.
[4] Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide — Pirker R et al., Journal of Clinical Oncology 2008. PMID: 18467726. View sourceStudy: Randomized controlled trialDarbepoetin reduced transfusions without a demonstrable adverse effect on survival in this SCLC population.
[5] Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia — Bennett CL et al., JAMA 2008. PMID: 18314434. View sourceStudy: Meta-analysisESA therapy including darbepoetin was associated with increased venous thromboembolism and mortality in cancer.
[6] Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials — Bohlius J et al., Lancet 2009. PMID: 19410717. View sourceStudy: Meta-analysis of randomized trialsThe ESA class, which includes darbepoetin, increased on-study mortality and worsened survival in cancer.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.